よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (48 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
34. Armand-Lefevre L, et al. Emergence of imipenem-resistant gram-negative bacilli in
intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013.
57(3):1488-1495.
4
5
6
35. Ishikawa K, et al. In Vitro Activity and Clinical Efficacy of Faropenem against ThirdGeneration Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2022. 66(6):e0012522.
7
8
36. Eckburg PB, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract
Infection. N Engl J Med. 2022. 386(14):1327-1338.
9
10
11
37. Infectious Diseases Society of America 2024 Guidance on the Treatment of
Antimicrobial-Resistant Gram-Negative Infections. Tamma PD, Heil EL, Justo JA,
Mathers AJ, Satlin MJ, Bonomo RA. Clin Infect Dis. 2024. 7:ciae403.
12
13
14
15
38. Hamada Y, et al. Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of
Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing
Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal
Function. Antibiotics (Basel). 2022. 11(4):456.
16
17
18
39. Hayakawa K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary
tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Antimicrob Agents Chemother. 2023. 67(10):e0051023.
19
20
40. JAID/JSC 感染症治療ガイド・ガイドライン作成委員会 JAID/JSC 感染症治療ガイド
2023.
21
22
23
41. Lo CL, et al. Fluoroquinolone therapy for bloodstream infections caused by extendedspectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J
Microbiol Immunol Infect. 2017. 50(3):355-61.
24
25
42. Rodriguez-Bano J, et al. Community infections caused by extended-spectrum βlactamase-producing Escherichia coli. Arch Intern Med. 2008. 168(17):1897-1902.
26
27
28
43. Punjabi C, et al. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. β-lactams
as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and
Meta-analysis. Open Forum Infect Dis. 2019. 6(10):ofz364.
29
30
44. Hooton TM, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of
uncomplicated cystitis in women: a randomized trial. JAMA. 2005. 293(8):949-55.
31
32
33
34
45. Matsumura Y, et al. In vitro activities and detection performances of cefmetazole and
flomoxef for extended-spectrum beta-lactamase and plasmid-mediated AmpC betalactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016. 84(4):322327.
35
36
37
46. Tamma PD, et al. Antibacterial Resistance Leadership G. A Primer on AmpC βLactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clin
Infect Dis. 2019. 69(8):1446-1455.
38
39
47. 西村翔. よくわかっているようでよくわかっていない AmpC のハナシ(1). J-IDEO. 2017.
1(3):343-350.
40
41
42
48. Kohlmann R, et al. Species-specific mutation rates for ampC derepression in
Enterobacterales with chromosomally encoded inducible AmpC β-lactamase. J
Antimicrob Chemother. 2018. 73(6):1530-1536.
43
44
49. Tamma PD, et al. The use of cefepime for treating AmpC β-lactamase-producing
Enterobacteriaceae. Clin Infect Dis. 2013. 57(6):781-788.
45
46
50. Maillard A, et al. Mutation Rate of AmpC β-Lactamase-Producing Enterobacterales and
Treatment in Clinical Practice: A Word of Caution. Clin Infect Dis. 2024. 79(1):52-55.
48
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
34. Armand-Lefevre L, et al. Emergence of imipenem-resistant gram-negative bacilli in
intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013.
57(3):1488-1495.
4
5
6
35. Ishikawa K, et al. In Vitro Activity and Clinical Efficacy of Faropenem against ThirdGeneration Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2022. 66(6):e0012522.
7
8
36. Eckburg PB, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract
Infection. N Engl J Med. 2022. 386(14):1327-1338.
9
10
11
37. Infectious Diseases Society of America 2024 Guidance on the Treatment of
Antimicrobial-Resistant Gram-Negative Infections. Tamma PD, Heil EL, Justo JA,
Mathers AJ, Satlin MJ, Bonomo RA. Clin Infect Dis. 2024. 7:ciae403.
12
13
14
15
38. Hamada Y, et al. Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of
Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing
Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal
Function. Antibiotics (Basel). 2022. 11(4):456.
16
17
18
39. Hayakawa K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary
tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Antimicrob Agents Chemother. 2023. 67(10):e0051023.
19
20
40. JAID/JSC 感染症治療ガイド・ガイドライン作成委員会 JAID/JSC 感染症治療ガイド
2023.
21
22
23
41. Lo CL, et al. Fluoroquinolone therapy for bloodstream infections caused by extendedspectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J
Microbiol Immunol Infect. 2017. 50(3):355-61.
24
25
42. Rodriguez-Bano J, et al. Community infections caused by extended-spectrum βlactamase-producing Escherichia coli. Arch Intern Med. 2008. 168(17):1897-1902.
26
27
28
43. Punjabi C, et al. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. β-lactams
as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and
Meta-analysis. Open Forum Infect Dis. 2019. 6(10):ofz364.
29
30
44. Hooton TM, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of
uncomplicated cystitis in women: a randomized trial. JAMA. 2005. 293(8):949-55.
31
32
33
34
45. Matsumura Y, et al. In vitro activities and detection performances of cefmetazole and
flomoxef for extended-spectrum beta-lactamase and plasmid-mediated AmpC betalactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016. 84(4):322327.
35
36
37
46. Tamma PD, et al. Antibacterial Resistance Leadership G. A Primer on AmpC βLactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clin
Infect Dis. 2019. 69(8):1446-1455.
38
39
47. 西村翔. よくわかっているようでよくわかっていない AmpC のハナシ(1). J-IDEO. 2017.
1(3):343-350.
40
41
42
48. Kohlmann R, et al. Species-specific mutation rates for ampC derepression in
Enterobacterales with chromosomally encoded inducible AmpC β-lactamase. J
Antimicrob Chemother. 2018. 73(6):1530-1536.
43
44
49. Tamma PD, et al. The use of cefepime for treating AmpC β-lactamase-producing
Enterobacteriaceae. Clin Infect Dis. 2013. 57(6):781-788.
45
46
50. Maillard A, et al. Mutation Rate of AmpC β-Lactamase-Producing Enterobacterales and
Treatment in Clinical Practice: A Word of Caution. Clin Infect Dis. 2024. 79(1):52-55.
48